Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 MilestonesGlobeNewsWire • 01/12/25
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded UseZacks Investment Research • 01/07/25
European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)GlobeNewsWire • 01/06/25
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)GlobeNewsWire • 12/20/24
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman SyndromeGlobeNewsWire • 12/19/24
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science SummitGlobeNewsWire • 11/09/24
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat EstimatesZacks Investment Research • 11/06/24
RARE's Wilson Disease Candidate Betters Standard Therapy in StudyZacks Investment Research • 10/04/24
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseGlobeNewsWire • 10/03/24
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual MeetingGlobeNewsWire • 09/26/24
Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LPBusiness Wire • 08/02/24
Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/02/24